57 related articles for article (PubMed ID: 28512718)
1. Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data.
Mittapalli RK; Marroum P; Qiu Y; Apfelbaum K; Xiong H
Pharm Res; 2017 Jul; 34(7):1527-1533. PubMed ID: 28512718
[TBL] [Abstract][Full Text] [Related]
2. Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
Mohamed MF; Trueman S; Othman AA; Han JH; Ju TR; Marroum P
AAPS J; 2019 Oct; 21(6):108. PubMed ID: 31654328
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
Kesisoglou F; Xia B; Agrawal NG
AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
[TBL] [Abstract][Full Text] [Related]
4. A convolution-based in vitro-in vivo correlation model for methylphenidate hydrochloride delayed-release and extended-release capsule.
Gupta PK; Incledon B; Gobburu JVS; Gomeni R
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):132-142. PubMed ID: 37864318
[TBL] [Abstract][Full Text] [Related]
5. Conventional vs Mechanistic IVIVC: A Comparative Study in Establishing Dissolution Safe Space for Extended Release Formulations.
Kollipara S; Ahmed T; Chougule M; Guntupalli C; Sivadasu P
AAPS PharmSciTech; 2024 May; 25(5):118. PubMed ID: 38806735
[TBL] [Abstract][Full Text] [Related]
6. Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations.
Gomez-Mantilla JD; Schaefer UF; Casabo VG; Lehr T; Lehr CM
AAPS J; 2014 Jul; 16(4):791-801. PubMed ID: 24854895
[TBL] [Abstract][Full Text] [Related]
7. Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.
Miranda Dos Santos E; Ferraz HG; Issa MG; Duque MD
J Pharm Sci; 2023 Dec; 112(12):3131-3140. PubMed ID: 37473918
[TBL] [Abstract][Full Text] [Related]
8. Towards in vitro - In vivo correlation models for in situ forming drug implants.
Wang X; Roy M; Wang R; Kwok O; Wang Y; Wang Y; Qin B; Burgess DJ
J Control Release; 2024 Jun; 372():648-660. PubMed ID: 38936743
[TBL] [Abstract][Full Text] [Related]
9. IVIVC Revised.
Alimpertis N; Simitopoulos A; Tsekouras AA; Macheras P
Pharm Res; 2024 Feb; 41(2):235-246. PubMed ID: 38191705
[TBL] [Abstract][Full Text] [Related]
10. Candesartan Cilexetil In Vitro-In Vivo Correlation: Predictive Dissolution as a Development Tool.
Figueroa-Campos A; Sánchez-Dengra B; Merino V; Dahan A; González-Álvarez I; García-Arieta A; González-Álvarez M; Bermejo M
Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32640620
[TBL] [Abstract][Full Text] [Related]
11. In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs.
Rojas Gómez R; Restrepo Valencia P
Colomb Med (Cali); 2015 Sep; 46(3):109-16. PubMed ID: 26600625
[TBL] [Abstract][Full Text] [Related]
12. Miniaturized screening and performance prediction of tailored subcutaneous extended-release formulations for preclinical in vivo studies.
Block M; Sieger P; Truenkle C; Saal C; Simon R; Truebenbach I
Eur J Pharm Sci; 2024 May; 196():106733. PubMed ID: 38408709
[TBL] [Abstract][Full Text] [Related]
13. Accelerated and Biopredictive In Vitro Release Testing Strategy for Single Agent and Combination Long-Acting Injectables.
Jain KMH; Ho T; Hoe S; Wan B; Muthal A; Subramanian R; Foti C
J Pharm Sci; 2024 Jul; 113(7):1885-1897. PubMed ID: 38369022
[TBL] [Abstract][Full Text] [Related]
14. In vitro-in vivo correlations: tricks and traps.
Cardot JM; Davit BM
AAPS J; 2012 Sep; 14(3):491-9. PubMed ID: 22547350
[TBL] [Abstract][Full Text] [Related]
15. Use of
da Silva Honório T; Simon A; Machado RMC; Rodrigues CR; do Carmo FA; Cabral LM; de Sousa VP
Curr Pharm Des; 2023; 29(38):3040-3049. PubMed ID: 37957861
[TBL] [Abstract][Full Text] [Related]
16. Impact of data base structure in a successful in vitro-in vivo correlation for pharmaceutical products.
Roudier B; Davit B; Schütz H; Cardot JM
AAPS J; 2015 Jan; 17(1):24-34. PubMed ID: 25387995
[TBL] [Abstract][Full Text] [Related]
17. From in vitro to in vivo: A comprehensive guide to IVIVC development for long-acting therapeutics.
Pastorin G; Benetti C; Wacker MG
Adv Drug Deliv Rev; 2023 Aug; 199():114906. PubMed ID: 37286087
[No Abstract] [Full Text] [Related]
18. Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model.
Huber HJ; Mistry HB
J Pharmacokinet Pharmacodyn; 2024 Apr; 51(2):169-185. PubMed ID: 37930506
[TBL] [Abstract][Full Text] [Related]
19. Reassessing models of hepatic extraction.
Ridgway D; Tuszynski JA; Tam YK
J Biol Phys; 2003 Mar; 29(1):1-21. PubMed ID: 23345816
[TBL] [Abstract][Full Text] [Related]
20. Potassium chloride: A high risk drug for medication error.
Kothari D; Kothari S; Agrawal J
Indian J Anaesth; 2012 Jan; 56(1):90-1. PubMed ID: 22529434
[No Abstract] [Full Text] [Related]
[Next] [New Search]
